RU99120377A - STABLE COMPLEXES OF WEAKLY CONNECTED COMPOUNDS - Google Patents
STABLE COMPLEXES OF WEAKLY CONNECTED COMPOUNDSInfo
- Publication number
- RU99120377A RU99120377A RU99120377/14A RU99120377A RU99120377A RU 99120377 A RU99120377 A RU 99120377A RU 99120377/14 A RU99120377/14 A RU 99120377/14A RU 99120377 A RU99120377 A RU 99120377A RU 99120377 A RU99120377 A RU 99120377A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutical composition
- ionic polymer
- polymer
- therapeutically active
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 49
- 229920000831 ionic polymer Polymers 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 229920000642 polymer Polymers 0.000 claims 17
- 239000011521 glass Substances 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 8
- 239000011159 matrix material Substances 0.000 claims 6
- 125000000129 anionic group Chemical group 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 3
- 238000001556 precipitation Methods 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- XIBPCLQLEGQADN-UHFFFAOYSA-M 4-acetyloxy-4-oxobutanoate Chemical compound CC(=O)OC(=O)CCC([O-])=O XIBPCLQLEGQADN-UHFFFAOYSA-M 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002301 Cellulose acetate Polymers 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 229920003148 Eudragit® E polymer Polymers 0.000 claims 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- FMTQGBMMIVVKSN-UHFFFAOYSA-N acetic acid;terephthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=C(C(O)=O)C=C1 FMTQGBMMIVVKSN-UHFFFAOYSA-N 0.000 claims 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical group COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229940113088 dimethylacetamide Drugs 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- ZLPMUYAOHZTBEV-UHFFFAOYSA-N ethoxyethane;2-(2-hydroxyethoxy)ethanol Chemical compound CCOCC.OCCOCCO ZLPMUYAOHZTBEV-UHFFFAOYSA-N 0.000 claims 1
- XHIOOWRNEXFQFM-UHFFFAOYSA-N ethyl prop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.CCOC(=O)C=C XHIOOWRNEXFQFM-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920002721 polycyanoacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
Claims (1)
7. Фармацевтическая композиция по п.1, где ионный полимер представляет собой анионный полимер.6. The pharmaceutical composition according to claim 5, wherein the cationic polymer is Eudragit E ® .
7. The pharmaceutical composition according to claim 1, where the ionic polymer is an anionic polymer.
10. Фармацевтическая композиция по п.7, где анионный полимер выбирают из группы, включающей фталат поливинилацетата, фталат ацетилцеллюлозы, фталат гидроксипропилметилцеллюлозы, терефталат ацетилцеллюлозы, полицианакрилат, ацетилсукцинат гидроксипропилметилцеллюлозы, карбоксиметилцеллюлозу и гидроксипропилцеллюлозу с небольшим количеством замещений.9. The pharmaceutical composition of claim 8, where the anionic polymer is selected from the group including
10. The pharmaceutical composition according to claim 7, where the anionic polymer is selected from the group including polyvinyl acetate phthalate, cellulose phthalate, hydroxypropylmethylcellulose phthalate, cellulose acetate terephthalate, polycyanoacrylate, hydroxypropylmethylcellulose acetyl succinate, carboxymethylcellulose, and I and I will be a part of the template.
(а) растворение терапевтически активного соединения и ионного полимера в пригодном растворителе,
(б) приведение раствора, полученного на стадии (а), в контакт с водным раствором, имеющим значение рН, при котором ионный полимер слабо растворим, что вызывает микроосаждение терапевтически активного соединения и ионного полимера в виде комплекса соединение/полимер,
(в) приготовление фармацевтической композиции, содержащей комплекс соединение/полимер, полученный выше на стадии (б).22. A method for preparing a pharmaceutical composition comprising a water-insoluble complex consisting of a stable amorphous therapeutically active compound and an ionic polymer, comprising:
(a) dissolving the therapeutically active compound and ionic polymer in a suitable solvent,
(b) bringing the solution obtained in stage (a) into contact with an aqueous solution having a pH value at which the ionic polymer is slightly soluble, which causes microtherapy of the therapeutically active compound and the ionic polymer as a compound / polymer complex,
(c) preparation of a pharmaceutical composition comprising the compound / polymer complex obtained in step (b) above.
(а) растворение терапевтически активного соединения в его кристаллической форме и ионного полимера в органическом растворителе,
(б) введение продукта, полученного на стадии (а), в контакт с водным раствором, имеющим значение рН, при котором ионный полимер и терапевтически активное соединение осаждаются в виде матрицы соединение/полимер,
(в) промывку матрицы соединение/полимер,
(г) сушку матрицы соединение/полимер и
(д) приготовление фармацевтической композиции, содержащей промытую и высушенную матрицу соединение/полимер, полученную выше на стадии (г).30. A method for preparing a pharmaceutical composition comprising a water-insoluble complex of a stable amorphous therapeutically active compound and an ionic polymer, comprising:
(a) dissolving the therapeutically active compound in its crystalline form and ionic polymer in an organic solvent,
(b) contacting the product obtained in step (a) with an aqueous solution having a pH value at which the ionic polymer and the therapeutically active compound are deposited as a compound / polymer matrix,
(c) washing the compound / polymer matrix,
(g) drying the compound / polymer matrix and
(e) the preparation of a pharmaceutical composition containing the washed and dried compound / polymer matrix obtained above in step (d).
33. Способ приготовления водонерастворимого комплекса стабильного аморфного соединения и ионного полимера, включающий:
(а) сплавление вместе терапевтически активного соединения и ионного полимера и
(б) охлаждение смеси, полученной на стадии (а).32. The method according to p, where the ionic polymer is chosen from the group including
33. A method for preparing a water-insoluble complex of a stable amorphous compound and an ionic polymer, comprising:
(a) fusing together a therapeutically active compound and an ionic polymer; and
(b) cooling the mixture obtained in stage (a).
(а) растворение терапевтически активного соединения и ионного полимера в сверхкритической жидкости,
(б) удаление сверхкритической жидкости, в результате чего происходит микроосаждение терапевтически активного соединения в полимерной матрице, и
(в) приготовление фармацевтической композиции, содержащей продукт, полученный выше на стадии (б).34. A method for preparing a pharmaceutical composition comprising a water-insoluble complex of a stable amorphous compound and an ionic polymer, comprising:
(a) dissolving a therapeutically active compound and an ionic polymer in a supercritical fluid,
(b) removing the supercritical fluid, resulting in micro-precipitation of the therapeutically active compound in the polymer matrix, and
(c) the preparation of a pharmaceutical composition containing the product obtained in step (b) above.
(а) растворения соединения I и водонерастворимого ионного полимера, имеющего молекулярную массу больше приблизительно 80000 Да и температуру стеклования, равную или превышающую приблизительно 50°С, в пригодном растворителе и
(б) совместного осаждения соединения I и ионогенного полимера в виде комплекса соединение/полимер.38. Stable water-insoluble complex obtained by:
(a) dissolving compound I and a water-insoluble ionic polymer having a molecular weight greater than about 80,000 Da and a glass transition temperature equal to or greater than about 50 ° C in a suitable solvent, and
(b) co-precipitating compound I and an ionic polymer in the form of a compound / polymer complex.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10133698P | 1998-09-22 | 1998-09-22 | |
US60/101,336 | 1998-09-22 | ||
US13653199P | 1999-05-28 | 1999-05-28 | |
US60/136,531 | 1999-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99120377A true RU99120377A (en) | 2001-06-27 |
RU2240827C2 RU2240827C2 (en) | 2004-11-27 |
Family
ID=26798138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99120377/15A RU2240827C2 (en) | 1998-09-22 | 1999-09-21 | Pharmaceutical composition, methods for its preparing, stable water-insoluble complexes, method for conversion of therapeutically active compound and therapeutically active compound |
Country Status (33)
Country | Link |
---|---|
US (1) | US6350786B1 (en) |
EP (1) | EP0988863B2 (en) |
JP (5) | JP2000095708A (en) |
KR (1) | KR100362019B1 (en) |
CN (1) | CN1201821C (en) |
AR (2) | AR022096A1 (en) |
AT (1) | ATE265232T1 (en) |
AU (1) | AU770745B2 (en) |
BR (1) | BR9904283A (en) |
CA (1) | CA2282906C (en) |
CO (1) | CO5140077A1 (en) |
CZ (1) | CZ300215B6 (en) |
DE (1) | DE69916733T3 (en) |
DK (1) | DK0988863T4 (en) |
ES (1) | ES2218918T5 (en) |
HK (1) | HK1026632A1 (en) |
HR (1) | HRP990287B1 (en) |
HU (1) | HU228341B1 (en) |
ID (1) | ID24034A (en) |
IL (1) | IL131957A (en) |
MA (1) | MA26692A1 (en) |
MY (1) | MY124377A (en) |
NO (1) | NO326928B1 (en) |
NZ (1) | NZ337884A (en) |
PE (1) | PE20001049A1 (en) |
PL (1) | PL202757B1 (en) |
PT (1) | PT988863E (en) |
RS (1) | RS50193B (en) |
RU (1) | RU2240827C2 (en) |
SG (1) | SG97131A1 (en) |
SI (1) | SI0988863T2 (en) |
TR (1) | TR199902324A3 (en) |
TW (1) | TWI234465B (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2307482T3 (en) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | SOLID PHARMACEUTICAL DISPERSIONS. |
US6440959B1 (en) | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
AR033651A1 (en) * | 1999-10-01 | 2004-01-07 | Hoffmann La Roche | DERIVATIVES OF PYRIMIDINE-2,4,6-TRIONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
JP4786113B2 (en) * | 2000-05-16 | 2011-10-05 | オーソーマクニール ファーマシューティカル, インコーポレイテッド | Method for coating medical devices using supercritical carbon dioxide |
US6482847B2 (en) | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US6469179B1 (en) | 2000-10-03 | 2002-10-22 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US6716845B2 (en) | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
EP1401404B1 (en) * | 2001-05-30 | 2008-04-16 | Csir | Method of encapsulating an active substance |
US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
ATE444060T1 (en) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS |
DE60237602D1 (en) | 2001-06-22 | 2010-10-21 | Bend Res Inc | PHARMACEUTICAL COMPOSITION CONTAINING HEAVY SOLUBLE AND ACIDIC TOXIC SUBSTANCES AND NEUTRALIZED ANIONIC POLYMERS |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
CN1309370C (en) * | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
WO2004014342A1 (en) | 2002-08-12 | 2004-02-19 | Pfizer Products Inc. | Pharmaceutical compositions of semi-ordered drugs and polymers |
DE10351087A1 (en) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Solid active ingredient formulation |
JP4947482B2 (en) * | 2003-11-14 | 2012-06-06 | 味の素株式会社 | Sustained release oral administration of phenylalanine derivatives |
CN101664411A (en) | 2003-11-14 | 2010-03-10 | 味之素株式会社 | Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative |
KR100771411B1 (en) * | 2004-04-01 | 2007-10-30 | 에프. 호프만-라 로슈 아게 | Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones |
AR049915A1 (en) * | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | COMPOUNDS WITH BORO CONTENT AND METHODS OF USE OF THE SAME |
WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
CN101115469A (en) * | 2004-12-28 | 2008-01-30 | 卫材R&D管理有限公司 | Quick disintegration tablet and method of producing the same |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
KR101238525B1 (en) * | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Novel benzylamine derivatives as cetp inhibitors |
EP1690528A1 (en) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent |
EP1885338A1 (en) * | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
EP1767194A1 (en) * | 2005-06-09 | 2007-03-28 | Helm AG | Process for the preparation of adsorbates of drospirenone |
BRPI0611863B1 (en) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | COMPOUND, AS WELL AS COMPOSITION AND KIT COMPRISING THE SAME, INTERMEDIATE COMPOUND IN THE PREPARATION OF THE SAME, METHOD FOR TREATMENT AND USE OF THE SAME |
US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
BRPI0714265A2 (en) * | 2006-08-10 | 2013-04-16 | Cipla Ltd | solid oral composition, process for preparing a solid oral composition, use of a composition and method for treating HIV |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (en) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
WO2008081829A1 (en) | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | Aminoalkylmethacrylate copolymer e for maintaining solubility of poorly water-soluble drug |
CN101702878B (en) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | Pharmaceutical compositions for poorly soluble drugs |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
EP1997479A1 (en) * | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
EP2214635A1 (en) * | 2007-10-19 | 2010-08-11 | Purdue Research Foundation | Solid formulations of crystalline compounds |
US7794750B2 (en) * | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
KR20100073454A (en) * | 2008-12-23 | 2010-07-01 | 국립암센터 | Novel pyrazolodiazepine compound as an transglutaminase inhibitor, the preparation method thereof and a composition containing the same |
MY172424A (en) * | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
BR112012012156A2 (en) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compounds and methods for kinase modulation, and indications for this |
KR20130126451A (en) * | 2010-05-31 | 2013-11-20 | 아스테라스 세이야쿠 가부시키가이샤 | Solid dispersion comprising triazole compound |
TR201816421T4 (en) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Compounds and methods for kinase modulation and their indications. |
CN103391769A (en) | 2011-02-17 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
CN108498465B (en) * | 2011-10-14 | 2022-05-17 | 阵列生物制药公司 | Solid dispersions of an ErbB2(HER2) inhibitor |
SI2827900T1 (en) | 2012-03-23 | 2018-06-29 | Array Biopharma, Inc. | Amorphous solid dispersion for use in the treatment of brain cancer |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JO3339B1 (en) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
RU2015123632A (en) | 2012-11-19 | 2017-01-10 | Др. Редди'С Лабораторис Лтд. | PHARMACEUTICAL COMPOSITIONS OF CETR INHIBITORS |
CN105007899A (en) * | 2012-12-20 | 2015-10-28 | 卡希夫制药有限责任公司 | Orally disintegrating tablet formulation for enhanced bioavailability |
MY192032A (en) | 2013-01-22 | 2022-07-24 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
TWI615157B (en) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | Solid dispersion comprising amorphous cilostazol |
US20160213575A1 (en) * | 2013-09-11 | 2016-07-28 | 3M Innovative Properties Company | Coating compositions, dental structures thereof and methods for generating contrast |
US20160303102A1 (en) * | 2013-12-05 | 2016-10-20 | Alrise Biosystems Gmbh | Process for the production of drug formulations for oral administration |
PT107846B (en) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Production of Amorphous Solid Dispersion Nanoparticles by Controlled Co-Precipitation |
BR112017025739A2 (en) * | 2015-05-29 | 2018-08-07 | Sun Pharmaceutical Ind Ltd | isotretinoin oral pharmaceutical composition having increased bioavailability, process for preparing it and method of treatment |
EP3447056A4 (en) | 2016-12-13 | 2019-09-18 | Nanjing Transthera Biosciences Co. Ltd. | Multi-kinase inhibitor compound, and crystal form and use thereof |
KR20200014298A (en) | 2017-04-28 | 2020-02-10 | 시애틀 지네틱스, 인크. | Treatment of HER2-positive cancer |
KR102082775B1 (en) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | Formulation with enhanced water solubility and bioavailability |
RU2725879C2 (en) * | 2018-07-26 | 2020-07-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Interpolymer carrier for oral systems of controlled delivery of active pharmaceutical ingredients |
JP2022509965A (en) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R, 3S) -6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl) -1,2,2-trimethylpiperazine and 4-((1R, 3S)- Prodrug of 6-chloro-3- (phenyl-d5) -2,3-dihydro-1H-indene-1-yl) -2,2-dimethyl-1- (methyl-d3) piperazine |
EP4093379A1 (en) | 2020-01-24 | 2022-11-30 | Nanocopoeia LLC | Amorphous solid dispersions of dasatinib and uses thereof |
IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
KR20220129628A (en) | 2020-03-03 | 2022-09-23 | 데쿠세리아루즈 가부시키가이샤 | Method for manufacturing an image display device |
EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
FI864812A (en) * | 1985-11-27 | 1987-05-28 | Syntex Inc | FOERFARANDE FOER FRAMSTAELLNING AV AMORFA BENSIMIDAZOLDERIVAT. |
CZ280738B6 (en) * | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituted pyrroles, their use for preparing medicaments and medicaments based thereon |
JP2528706B2 (en) † | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | Pharmaceutical composition of dihydropyridine compound |
USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH0729926B2 (en) † | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | Composition for easily absorbable preparations |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU1537292A (en) † | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
GB9511220D0 (en) † | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
ATE240734T1 (en) * | 1995-07-26 | 2003-06-15 | Kyowa Hakko Kogyo Kk | PREPARATION OF XANTHINDERIVATES AS A SOLID DISPERSION |
AU7106996A (en) † | 1995-09-07 | 1997-03-27 | Fuisz Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
DE19548624A1 (en) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | New barbituric acid derivatives, processes for their preparation and medicaments containing these compounds |
JPH09208459A (en) * | 1996-02-07 | 1997-08-12 | Eisai Co Ltd | Preparation improved in solubility |
JP3737518B2 (en) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー, エル.ピー. | Water-soluble paclitaxel prodrug |
JP2000514057A (en) * | 1996-06-28 | 2000-10-24 | シェーリング コーポレイション | Solid solution of antifungal agent with enhanced bioavailability |
PE91598A1 (en) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | SUBSTITUTED PYRROLES |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
CZ299068B6 (en) | 1998-03-17 | 2008-04-16 | F. Hoffmann-La Roche Ag | Substituted bisindolylmaleimide and pharmaceutical composition containing thereof |
-
1999
- 1999-09-07 US US09/391,060 patent/US6350786B1/en not_active Expired - Lifetime
- 1999-09-13 AT AT99117908T patent/ATE265232T1/en active
- 1999-09-13 DE DE69916733T patent/DE69916733T3/en not_active Expired - Lifetime
- 1999-09-13 SI SI9930573T patent/SI0988863T2/en unknown
- 1999-09-13 ES ES99117908T patent/ES2218918T5/en not_active Expired - Lifetime
- 1999-09-13 DK DK99117908T patent/DK0988863T4/en active
- 1999-09-13 PT PT99117908T patent/PT988863E/en unknown
- 1999-09-13 EP EP99117908A patent/EP0988863B2/en not_active Expired - Lifetime
- 1999-09-16 IL IL13195799A patent/IL131957A/en not_active IP Right Cessation
- 1999-09-17 NZ NZ337884A patent/NZ337884A/en not_active IP Right Cessation
- 1999-09-17 PE PE1999000947A patent/PE20001049A1/en not_active IP Right Cessation
- 1999-09-17 SG SG9904570A patent/SG97131A1/en unknown
- 1999-09-17 CZ CZ0330499A patent/CZ300215B6/en not_active IP Right Cessation
- 1999-09-17 CO CO99059117A patent/CO5140077A1/en unknown
- 1999-09-20 AU AU48807/99A patent/AU770745B2/en not_active Expired
- 1999-09-20 ID IDP990878D patent/ID24034A/en unknown
- 1999-09-20 HR HR990287 patent/HRP990287B1/en not_active IP Right Cessation
- 1999-09-20 CA CA2282906A patent/CA2282906C/en not_active Expired - Lifetime
- 1999-09-20 TW TW088116184A patent/TWI234465B/en not_active IP Right Cessation
- 1999-09-20 HU HU9903189A patent/HU228341B1/en unknown
- 1999-09-20 MY MYPI99004065A patent/MY124377A/en unknown
- 1999-09-20 AR ARP990104725A patent/AR022096A1/en not_active Application Discontinuation
- 1999-09-21 MA MA25778A patent/MA26692A1/en unknown
- 1999-09-21 JP JP11267142A patent/JP2000095708A/en not_active Withdrawn
- 1999-09-21 NO NO19994583A patent/NO326928B1/en not_active IP Right Cessation
- 1999-09-21 RU RU99120377/15A patent/RU2240827C2/en active
- 1999-09-21 RS YUP-473/99A patent/RS50193B/en unknown
- 1999-09-21 TR TR1999/02324A patent/TR199902324A3/en unknown
- 1999-09-21 CN CNB991194063A patent/CN1201821C/en not_active Expired - Lifetime
- 1999-09-21 BR BR9904283-5A patent/BR9904283A/en not_active Application Discontinuation
- 1999-09-22 PL PL335592A patent/PL202757B1/en unknown
- 1999-09-22 KR KR1019990041130A patent/KR100362019B1/en active IP Right Grant
-
2000
- 2000-09-19 HK HK00105891A patent/HK1026632A1/en not_active IP Right Cessation
-
2007
- 2007-06-06 JP JP2007150911A patent/JP2007224048A/en active Pending
-
2011
- 2011-04-13 AR ARP110101253A patent/AR080892A2/en not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230446A patent/JP6253135B2/en not_active Expired - Lifetime
-
2015
- 2015-07-16 JP JP2015141952A patent/JP2015187170A/en active Pending
-
2016
- 2016-08-31 JP JP2016169245A patent/JP6534979B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99120377A (en) | STABLE COMPLEXES OF WEAKLY CONNECTED COMPOUNDS | |
CA2282906A1 (en) | Stable complexes of poorly soluble compounds | |
US4882144A (en) | Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation | |
EP1423096B1 (en) | A process for preparing crystalline drug particles by means of precipitation | |
RU2000102637A (en) | METHOD FOR PREPARATION OF PAROXETIN SOLID DISPERSIONS | |
US5925776A (en) | Polyethoxylated castor oil, process of making the same and formulations thereof | |
JPS5831210B2 (en) | antennae | |
NO885570D0 (en) | PROCEDURE FOR THE PREPARATION OF A WATER SOLUBLE POLYMER POWDER REDEPABLE IN A FLUID PHASE; THE POWDER COLLECTED AND USED THEREOF. | |
EP0889080A4 (en) | ||
JP2009502487A5 (en) | ||
CN103396521B (en) | The synthesis of amphipathic beta-cyclodextrin star-type polymer and micellization application thereof | |
CA2293728A1 (en) | Nanocapsules based on water-dispersible anionic polymers, the process of preparing them, and cosmetic or dermatological compounds containing them | |
RU2006130733A (en) | METHOD FOR PRODUCING LOW CRYSTAL OLTIPRAZE OR AMORPHOUS OLTIPRAZE | |
RU2002105504A (en) | SOLID DISPERSING AGENT OF NON-CRYSTAL CEFUROXYM-AXETHYL, METHOD FOR ITS PREPARATION AND COMPOSITION FOR ITS Oral Administration | |
CN110354075A (en) | A kind of Loratadine nano suspension and preparation method thereof | |
WO2022257288A1 (en) | Method for synthesizing diltiazem hydrochloride and use thereof | |
AU2001272262A1 (en) | Drug delivery system for poorly water soluble drugs | |
CN111467344B (en) | Lacidipine solid dispersion and preparation method thereof | |
EP1192204A1 (en) | New process for the purification of aldehyde impurities | |
CN116963739A (en) | Amorphous solid dispersion formulation | |
WO2004071494A3 (en) | Lipophilic compositions | |
CA2175293A1 (en) | Pharmaceutical preparations having controlled release of active compound and processes for their preparation | |
KR910004197A (en) | Antimicrobial composition | |
USRE33963E (en) | Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation | |
CN1275968C (en) | Non crystalline tricyclic triazolobenzazepine derivative |